FAQ: Breaking down ACOG's updated guidance for evaluating postmenopausal bleeding

The American College of Obstetricians and Gynecologists (ACOG) has released updated clinical guidance for the evaluation of postmenopausal bleeding, responding to a steady increase in endometrial cancer incidence over recent decades. Given that approximately 90% of patients diagnosed with endometrial cancer present with postmenopausal bleeding, the update aims to provide a more robust framework for earlier and more comprehensive screening to ensure prompt diagnosis.¹

The revised guidance emphasizes a shift toward a dual-diagnostic approach to minimize the risk of missed malignancies. Although transvaginal ultrasonography has traditionally served as a primary triage tool, ACOG now highlights its limitations in sensitivity. The following FAQs outline the updated recommendations and the clinical rationale behind the transition to a more intensive initial evaluation process.

Frequently Asked Questions on the Evaluation of Postmenopausal Bleeding^1-3

1. What is the primary recommendation for the initial evaluation of postmenopausal bleeding?

The combination of both transvaginal ultrasonography and endometrial tissue sampling is recommended as part of the initial evaluation in most patients with postmenopausal bleeding.

2. Why has ACOG moved toward a dual-modality approach for initial screening?

Relying on ultrasound alone can impose a greater risk of missing a cancer diagnosis, with recent data suggesting that 5% to 12% of cancers may not be diagnosed on initial presentation.

“Current recommendations for using endometrial thickness by ultrasonography as a triage tool are associated with an unacceptably low sensitivity for malignant and premalignant endometrial pathology. By recommending tissue sampling as part of the initial evaluation for most patients, we are giving clinicians a more reliable path to detecting and treating uterine cancer.” —David Shalowitz, MD, MSHP, FACOG

3. Under what specific circumstances is transvaginal ultrasonography alone acceptable?

Transvaginal ultrasonography without endometrial biopsy may be used during initial evaluation of select patients with a single episode of postmenopausal bleeding and a sonographically fully visualized endometrium not thicker than 4 mm, without factors strongly associated with increased risk of endometrial cancer, who are counseled that continued or recurrent bleeding requires immediate re-evaluation, and for whom there are no significant barriers to prompt gynecologic evaluation.

4. How does ACOG define postmenopausal bleeding for the purposes of this guidance?

Postmenopausal bleeding is defined as bleeding presumed to be from the uterus 12 or more months after the final menstrual period.

5. What is the overarching goal of these updated recommendations?

The dual approach is intended to help clinicians promptly diagnose and treat endometrial cancer in patients who could be falsely reassured by ultrasound results alone.

“This guidance is designed to support clinicians to perform earlier and more comprehensive screenings. It gives clinicians a more robust framework for evaluating patients with postmenopausal bleeding—one that prioritizes prompt diagnosis and reduces the risk that a cancer is missed.” —Steven J. Fleischman, MD, MBA, FACOG

6. What are the specific trends in endometrial cancer incidence noted by the guidance?

The guidance noted a steady increase in endometrial cancer incidence in recent decades, specifically highlighting that incidence rose 2.7% per year through 2022 in Black women compared with 0.7% for White women.

7. How do mortality rates for endometrial cancer differ by race according to the update?

The risk of death because of endometrial cancer from 2019 to 2023 for non-Hispanic Black women was 9.8 per 100,000 women per year, which is more than twice the risk for non-Hispanic White women at 4.8 per 100,000 women per year.

8. How should clinicians approach the decision-making process for endometrial sampling?

The decision to proceed with endometrial sampling should result from shared decision-making and reflect patients’ values and preferences.

9. What role does patient-centered counseling play in the initial evaluation?

Early data indicate that patients are more likely to undergo endometrial sampling at their initial evaluation when clinicians engage in patient-centered counseling and share educational materials on the topic.

10. How does this guidance address care-associated burdens for patients?

The dual-approach strategy has the potential to reduce care-associated burdens for patients with limited access to easily accessible gynecologic, radiologic, and oncologic care by seeking a definitive diagnosis earlier in the process.

References:

1. Fitch J. ACOG updates guidance for evaluating postmenopausal bleeding. Contemporary OB/GYN. Published April 17, 2026. Accessed April 20, 2026. https://www.contemporaryobgyn.net/view/acog-updates-guidance-for-evaluating-postmenopausal-bleeding
2. ACOG publishes updated guidance on evaluation of postmenopausal bleeding. American College of Obstetricians & Gynecologists. News release. Published April 16, 2026. Accessed April 20, 2026. https://www.acog.org/news/news-releases/2026/04/acog-publishes-updated-guidance-evaluation-postmenopausal-bleeding
3. Updated Guidance Regarding The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Individuals With Postmenopausal Bleeding. Obstetrics & Gynecology. doi:10.1097/AOG.0000000000006275